Notes for P&L
All amounts in SEKm unless otherwise stated
Note 19 Non-current finanical assets
| Parent Company | ||||||
|---|---|---|---|---|---|---|
| Receivables from Group companies | 2023-12-31 | 2022-12-31 | ||||
| Opening balance | 7,599 | 6,589 | ||||
| Increase during the year | 0 | 2,282 | ||||
| Decrease during the year | -1,414 | -1,272 | ||||
| Carrying amount at year-end | 6,185 | 7,599 | ||||
| Specification of interests in Group companies | Country | Number of shares | Quotient value | Holding % | Carrying amount 2023-12-31 | Carrying amount 2022-12-31 |
| AddLife Development AB | Sweden | 1,000 | 100 | 100% | 1,619 | 389 |
| Interests in Group companies | Parent Company | |||||
| Accumulated cost | 2023 | 2022 | ||||
| Opening balance | 389 | 389 | ||||
| Acquisitions for the year | 1,230 | - | ||||
| Disposals for the year | - | - | ||||
| Closing balance | 1,619 | 389 | ||||
| Indirect ownership | |||||||
|---|---|---|---|---|---|---|---|
| Indirect ownership | Ownership | Indirect ownership | Ownership | Indirect ownership | Ownership | ||
| Biomedica Medizinprodukte GmbH | 100% | V-tech AB | 100% | BioNordika AS | 100% | ||
| Euromed Swiss AG | 100% | Väinö Korpinen Oy | 100% | BioNordika (Sweden) AB | 100% | ||
| Biomedis d.o.o. | 100% | Triolab Oy | 100% | BioNordika (Finland) Oy | 100% | ||
| Biomedica MP d.o.o. | 100% | Triolab AB | 100% | Dach Medical Group Holding AG | 100% | ||
| Biomedica Dijagnostika doo | 100% | Triolab (Baltics) Oy | 100% | Dach Austria Medical Group GmbH | 100% | ||
| Biomedica d.o.o. | 100% | LabRobot Products AB | 100% | Dach Switzerland Medical Group GmbH | 100% | ||
| Biomedica Bulgaria ood | 100% | BergmanLabora AB | 100% | D-A-CH Germany Medical Group GmbH | 100% | ||
| Biomedica Medizinprodukte Romania SRL | 100% | Biolin Scientific AB | 100% | Hepro AS | 100% | ||
| Biomedica Hungaria Kft. | 100% | Biolin Scientific China | 100% | Ropox A/S | 100% | ||
| Biomedica CS s.r.o. | 100% | Biolin Scientific Oy | 100% | Zafe Care Systems AB | 100% | ||
| Biomedica Poland Sp. Zo.o. | 100% | Biolin Scientific LTD | 100% | Biomedica Italia s.r.l | 100% | ||
| Biomedica Dijagnostika d.o.o.el | 100% | Holm & Halby A/S | 100% | Primacy Healthcare 21 Limited | 100% | ||
| Biomedica Slovakita s.r.o. | 100% | Medilas AG | 100% | Aquilant Northern Ireland Limited | 100% | ||
| Mediplast AB | 100% | Polytech Domilens GmbH | 100% | Aquilant Limited | 100% | ||
| Mediplast AS | 100% | M.E.D. Medical Products GmbH, Germany | 100% | Medscope Limited | 100% | ||
| Mediplast Sataside Oy | 100% | Vision Ophthalmology Holding One GmbH | 100% | Aquilant Endoscopy Limited | 100% | ||
| Mediplast S.r.l | 100% | Vision Ophthalmology Group GmbH | 100% | Healtcare Acquisitions Limited | 100% | ||
| Mediplast Benelux B.V. | 100% | Spectrum Ophthalmology Ltd | 100% | Tools For Living (Ireland) Limited | 100% | ||
| Mediplast GmbH | 100% | POLYMED Polska Sp.z.oo | 75% | Lyncare Systems Limited | 100% | ||
| Mediplast A/S | 100% | Visop Nordic AB | 100% | Healthcare 21 (UK) Limited | 100% | ||
| Mediplast Iberia SL | 100% | SSCP Blink BidCo Ltd | 100% | Healthcare 21 (DE) GmbH | 100% | ||
| Hospidana A/S | 100% | Vision Pharmaceuticals Ltd | 100% | Healthcare 21 (AT) GmbH | 100% | ||
| Fenno Medical Oy | 100% | MALA Holding B.V. | 100% | Primacy Healthcare 21 International Limited | 100% | ||
| TechniPro PulmoMed Pty Ltd | 100% | Bio-Connect B.V. | 100% | Asset Tracker Solutions Limited | 100% | ||
| Fischer Medical AS | 100% | Bio-Connect Diagnostics B.V. | 100% | Aquilant Scientific (ROI) Limited | 100% | ||
| Camanio AB | 100% | Bio-Connect Services B.V. | 100% | Aquilant Medical (ROI) Limited | 100% | ||
| Lab-Vent Controls A/S | 100% | European Warehousing Services B.V. | 100% | Xograph Healthcare Limited | 100% | ||
| Immuno Diagnostics Oy | 100% | Pharma-Connect B.V. | 100% | Xograph Healthcare (Ireland) Limited | 100% | ||
| Triolab AS | 100% | N.V. Forlab SA | 100% | Glanadh Medical Holdings Limited | 100% | ||
| EuroClone S.p.A. | 100% | MBA Incorporado S.L. | 100% | O'Flynn Medical Limited | 100% | ||
| Funksjonsutstyr AS | 76% | MBA Italia S.R.L | 100% | O'Flynn Innovation Limited | 100% | ||
| Svan Care AB | 100% | MBA Portugal S.A. | 100% | Emmat Norton Limited | 100% | ||
| AddVision Sweden AB | 100% | BioNordika (Denmark) A/S | 100% | BioCat GmbH | 100% | ||
Accounting principle
Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense.
To the top